EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies

Yi Lin iD, Benjamin Liou iD, Venette Fannin, Stuart Adler, Christopher N Mayhew, Jason E Hammonds, Yueh-Chiang Hu, Jason Tchieu iD, Wujuan Zhang, Xueheng Zhao, Rebecca L Beres, Kenneth D R Setchell und 4 weitere

eLife · 2026

DOI: 10.7554/elife.109518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Yi Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States. Hauptthemen laut MEDLINE: Gaucher Disease, Organoids, Mesencephalon, Glucosylceramidase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Health, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuronopathic Gaucher disease (nGD) is a lysosomal storage disorder caused by GBA1 mutations, leading to defective acid β-glucosidase (GCase) and accumulation of glycosphingolipid substrates, causing inflammation and neurodegeneration. Patients with nGD manifest severe neurological symptoms, but current animal models fail to fully recapitulate the human condition, posing a major barrier to the development of effective therapies targeting the brain. To bridge this gap, we have developed midbrain-like organoids (MLOs) from human induced pluripotent stem cells of nGD patients with GBA1 L444P/P415R and GBA1 L444P/RecNcil mutations to model nGD brain pathogenesis. These nGD MLOs exhibited GCase deficiency, resulting in diminished enzymatic function, accumulation of lipid substrates, widespread transcriptomic changes, and impaired dopaminergic neuron differentiation, mirroring nGD pathology. GBA1 mutation correction mediated by CRISPR/Cas9 restored GCase activity, normalized lipid substrate levels, and rescued dopaminergic neuron function, confirming the causal role of GBA1 mutations during early brain development. Using this novel platform, we further evaluated therapeutic strategies, including SapC-DOPS nanovesicles delivering GCase, AAV9-GBA1 gene therapy, and substrate reduction therapy with GZ452, a glucosylceramide synthase inhibitor currently under clinical investigation. These treatments either restored GCase activity, reduced lipid substrate accumulation, improved autophagic and lysosomal abnormalities, or ameliorated dysregulated genes involved in neural development. These patient-specific, 3D neural models offer a transformative, physiologically relevant platform for unraveling disease mechanisms and accelerating the discovery of therapies for patients with nGD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseaseOrganoidsMesencephalonGlucosylceramidaseCRISPR-Cas SystemsHumansPhenotypeMutationInduced Pluripotent Stem CellsDopaminergic Neurons

Stichwörter der Autor:innen

dopaminergic neuronsgene editinghumaniPSC disease modelinglipid metabolismmidbrain-like organoidsneuronopathic Gaucher diseaseneuroscienceregenerative medicinestem cells

Substanzen

GlucosylceramidaseGBA protein, human

Autor:innen und Institutionen

  • Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.
  • Pluripotent Stem Cell Facility and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
  • Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
  • Transgenic Animal and Genome Editing Facility, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
  • Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.

ORCID-Profile: Yi Lin, Benjamin Liou, Jason Tchieu, Ahmet Kaynak, Xiaoyang Qi, Ricardo A Feldman, Ying Sun

Förderung

  • NINDS NIH HHS
  • National Institute of Health
  • NICHD NIH HHS
  • Cincinnati Children's Hospital Medical Center
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Lin, Y., Liou, B., Fannin, V., Adler, S., Mayhew, C. N., Hammonds, J. E., Hu, Y. C., Tchieu, J., Zhang, W., Zhao, X., Beres, R. L., Setchell, K. D. R., Kaynak, A., Qi, X., Feldman, R. A., & Sun, Y. (2026). Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies. eLife. https://doi.org/10.7554/elife.109518

Vancouver

Lin Y, Liou B, Fannin V, Adler S, Mayhew CN, Hammonds JE, et al. Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies. eLife. 2026. doi:10.7554/elife.109518

BibTeX
@article{Lin2026,
  author = {Lin, Yi and Liou, Benjamin and Fannin, Venette and Adler, Stuart and Mayhew, Christopher N and Hammonds, Jason E and Hu, Yueh-Chiang and Tchieu, Jason and Zhang, Wujuan and Zhao, Xueheng and Beres, Rebecca L and Setchell, Kenneth D R and Kaynak, Ahmet and Qi, Xiaoyang and Feldman, Ricardo A and Sun, Ying},
  title = {Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies},
  journal = {eLife},
  year = {2026},
  doi = {10.7554/elife.109518}
}
Kostenlos starten →